In case of mCRPC with bone ± visceral mets after ADT + ARPI for mHSPC and DOC for 1st-line mCRPC, ¹⁷⁷Lu-PSMA-617 and CABA were deemed appropriate, based on the VISION , TheraP and CARD trials